Iovance Biotherapeutics Company Insiders
IOVA Stock | USD 8.55 0.31 3.76% |
Iovance Biotherapeutics employs about 557 people. The company is managed by 11 executives with a total tenure of roughly 1300 years, averaging almost 118.0 years of service per executive, having 50.64 employees per reported executive. Analysis of Iovance Biotherapeutics' management performance can provide insight into the company performance.
Iovance Biotherapeutics' Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
2024-11-12 | Ryan D Maynard | Disposed 50000 @ 10.06 | View | ||
2024-02-20 | Merrill A Mcpeak | Acquired 250000 @ 9.15 | View |
Monitoring Iovance Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Iovance |
Iovance Biotherapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Iovance Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Iovance will maintain a workforce of about 560 employees by December 2024.Iovance Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5665) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.85. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 496.1 M, whereas Total Current Assets are forecasted to decline to about 218.7 M.The current year's Common Stock Shares Outstanding is expected to grow to about 246.9 M, whereas Net Loss is projected to grow to (338.5 M).
Iovance Biotherapeutics Workforce Comparison
Iovance Biotherapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 5,846. Iovance Biotherapeutics holds roughly 557 in number of employees claiming about 10% of equities under Health Care industry.
Iovance Biotherapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iovance Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iovance Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Iovance Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.5 | 4 | 8 | 76,460 | 138,167 |
2024-09-01 | 0.5 | 10 | 20 | 161,490 | 236,976 |
2024-06-01 | 0.9167 | 11 | 12 | 340,116 | 64,194 |
2024-03-01 | 2.0 | 24 | 12 | 6,905,591 | 134,279 |
2023-12-01 | 0.5 | 3 | 6 | 26,461 | 38,102 |
2023-09-01 | 0.8333 | 5 | 6 | 5,036,460 | 38,101 |
2023-06-01 | 1.6667 | 10 | 6 | 426,000 | 38,099 |
2023-03-01 | 1.0833 | 13 | 12 | 1,224,156 | 241,130 |
2022-06-01 | 6.6667 | 20 | 3 | 1,511,709 | 25,501 |
2020-06-01 | 0.8333 | 5 | 6 | 210,000 | 181,782 |
2020-03-01 | 1.0 | 3 | 3 | 725,000 | 4,185 |
2019-09-01 | 0.3333 | 1 | 3 | 160,000 | 4,252 |
2019-06-01 | 1.6667 | 5 | 3 | 225,000 | 3,963 |
2019-03-01 | 1.0 | 3 | 3 | 700,000 | 4,422 |
2018-12-01 | 1.3333 | 4 | 3 | 1,243,053 | 3,963 |
2018-09-01 | 1.3333 | 4 | 3 | 175,000 | 3,963 |
2018-03-01 | 0.4 | 2 | 5 | 550,000 | 29,408 |
2017-12-01 | 0.2 | 1 | 5 | 37,400 | 218,581 |
2017-09-01 | 0.6667 | 2 | 3 | 400,000 | 5,981 |
2017-06-01 | 2.5 | 5 | 2 | 210,000 | 195,169 |
2016-09-01 | 1.3333 | 8 | 6 | 280,000 | 199,200 |
2015-06-01 | 2.5 | 5 | 2 | 340,000 | 2,830,682 |
2015-03-01 | 0.5 | 2 | 4 | 90,000 | 113,988 |
2014-12-01 | 8.0 | 8 | 1 | 319,073 | 100,000 |
2014-09-01 | 0.3333 | 1 | 3 | 125,000 | 400,000 |
2013-09-01 | 1.5 | 3 | 2 | 40,059,645 | 60,750,000 |
2013-06-01 | 0.4 | 4 | 10 | 976,846,104 | 50,008 |
2011-09-01 | 1.5 | 3 | 2 | 2,010,000 | 1,600,000 |
Iovance Biotherapeutics Notable Stakeholders
An Iovance Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Iovance Biotherapeutics often face trade-offs trying to please all of them. Iovance Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Iovance Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Esq JD | President, CEO | Profile | |
Igor Bilinsky | Chief Officer | Profile | |
Friedrich MD | Chief Officer | Profile | |
Howard MBA | Chief Officer | Profile | |
Kevin Smyth | Executive Quality | Profile | |
JeanMarc MBA | Chief Officer | Profile | |
Sara Pellegrino | Vice Relations | Profile | |
Madan Jagasia | Ex Affairs | Profile | |
Tracy Winton | Executive Resources | Profile | |
Brian MBA | Senior Technology | Profile | |
James MBA | Executive Commercial | Profile |
About Iovance Biotherapeutics Management Performance
The success or failure of an entity such as Iovance Biotherapeutics often depends on how effective the management is. Iovance Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Iovance management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Iovance management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.81) | (0.85) | |
Return On Capital Employed | (0.69) | (0.72) | |
Return On Assets | (0.57) | (0.60) | |
Return On Equity | (0.76) | (0.80) |
Please note, the presentation of Iovance Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iovance Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Iovance Biotherapeutics' management manipulating its earnings.
Iovance Biotherapeutics Workforce Analysis
Traditionally, organizations such as Iovance Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Iovance Biotherapeutics within its industry.Iovance Biotherapeutics Manpower Efficiency
Return on Iovance Biotherapeutics Manpower
Revenue Per Employee | 2.1K | |
Revenue Per Executive | 108.1K | |
Net Loss Per Employee | 797.2K | |
Net Loss Per Executive | 40.4M | |
Working Capital Per Employee | 354.7K | |
Working Capital Per Executive | 18M |
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |